Sacituzumab Govitecan: What It Is, How It Works, and Who It Helps

When you hear sacituzumab govitecan, a targeted cancer therapy that delivers chemotherapy directly to tumor cells. Also known as Trodelvy, it's not a traditional chemo drug—it’s an antibody-drug conjugate, meaning it uses a soldier-like antibody to find cancer cells and drop a powerful payload right on them. This precision matters because it spares healthy tissue better than older treatments, which often cause harsh side effects across the whole body.

Sacituzumab govitecan works by targeting a protein called TROP-2, which is found in high amounts on many cancer cells, especially in triple-negative breast cancer and some lung and bladder cancers. The antibody part of the drug locks onto TROP-2, then the attached chemo drug—SN-38—is released inside the cell to destroy it from within. This isn’t just theory: real-world data shows it helps people live longer when other treatments have failed. It’s not a cure, but for many, it’s a meaningful pause in disease progression.

It’s not for everyone. Doctors test for TROP-2 expression before prescribing it, and it’s mainly used after other therapies like chemo or immunotherapy don’t work anymore. Side effects like low white blood cell counts, diarrhea, and nausea are common, but manageable with the right support. What sets it apart is how it fits into the bigger picture of cancer care—moving from broad attacks to smart, targeted strikes. If you or someone you know is facing metastatic breast cancer or another TROP-2 positive tumor, this drug opens a real option where few existed before.

The posts below cover what you need to know about this treatment, from how it compares to other therapies to managing side effects and understanding the science behind it. You’ll find practical insights from people who’ve used it, and clear explanations of how it fits into modern oncology. No fluff. Just what works, what to watch for, and what’s next.